CClinicalTrials.gg
CompletedNCT02834520Updated Jul 15, 2016

Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus

An observational study in Oral Lichen Planus, sponsored by Cairo University. Completed. Open to participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-15.

Sponsored by Cairo University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
45 Years to 65 Years
Sex
All
01

Study summary

60 individuals were subdivided into 2 groups, 30 patients with oral lichen planus, 30 control individuals. Expression of miRNA-138 and cyclin D1 were evaluated in oral mucosa utilizing Quantitative real-time polymerase chain reaction and immunohistochemistry.

Read the detailed description

60 individuals were subdivided into 3 groups, into 2 groups, 30 patients with oral lichen planus, 30 control individuals having age, gender and periodontal status matched with both patients groups acting as a control group. Relative gene expression of miRNA-138 was estimated using Quantitative real-time polymerase chain reaction technique in oral mucosa of both oral lichen planus patients and control subjects. Sub grouping of oral lichen planus patients were performed into reticular, atrophic and erosive groups (n=10 each). Cyclin D1 gene expression was estimated using Quantitative real-time polymerase chain reaction technique and Cyclin D1 protein level was estimated using immunohistochemistry.

02

Conditions studied

  • Oral Lichen Planus
03

In context

Lichen Planus, Oral

139 studies on the registry are indexed under Lichen Planus, Oral; 24 are open to participants now.

This study's enrollment of 60 is below the median of 78 across 35 observational studies indexed under Lichen Planus, Oral.

Browse Lichen Planus, Oral studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

60 individuals were subdivided into 2 groups, 30 patients suffering from oral lichen planus and 30 individuals having age, gender and periodontal status matched with both patients groups acting as a control group.

Inclusion criteria

  • patients with oral lichen planus.

Exclusion criteria

Exclusion Criteria:

  • any systemic disease other than oral lichen planus.
  • smokers.
  • pregnant females.
  • periodontal diseases.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • oral lichen planus

    30 patients suffering from reticular, erosive and atrophic oral lichen planus

  • control subjects

    30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.

06

What researchers measure

Primary outcomes

  1. expression of miRNA-138

    expression of miRNA-138 in oral mucosa of patients with oral lichen planus

    Time frame: 1 day

Secondary outcomes

  1. gene expression of cyclin D1

    gene expression of cyclin D1 in oral mucosa of patients with oral lichen planus

    Time frame: 1 day

  2. protein expression of cyclin D1

    protein expression of cyclin D1 in oral mucosa of patients with oral lichen planus

    Time frame: 1 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, Shi F, Zhou X. Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer. 2010 Aug 1;127(3):505-12. doi: 10.1002/ijc.25320. PubMed 20232393 ↗
  • Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett. 2009 Dec 28;286(2):217-22. doi: 10.1016/j.canlet.2009.05.030. Epub 2009 Jun 21. PubMed 19540661 ↗
  • Jin Y, Chen D, Cabay RJ, Wang A, Crowe DL, Zhou X. Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma. Int Rev Cell Mol Biol. 2013;303:357-85. doi: 10.1016/B978-0-12-407697-6.00009-X. PubMed 23445815 ↗
  • Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K, Wu M, Liang Y, Liu P, Tang J, Lu WH, Feng QS, Chen LZ, Qian CN, Bei JX, Kang T, Zeng YX. MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle. 2012 Jul 1;11(13):2495-506. doi: 10.4161/cc.20898. Epub 2012 Jul 1. PubMed 22739938 ↗
  • Yao X, Yin C, Shen LJ, Xie SM. [Expressions of NF--kappaBp65, TRAF2, cyclinD1 and their association with cell apoptosis in oral lichen planus]. Nan Fang Yi Ke Da Xue Xue Bao. 2007 Nov;27(11):1657-60. Chinese. PubMed 18024283 ↗
  • Hirota M, Ito T, Okudela K, Kawabe R, Yazawa T, Hayashi H, Nakatani Y, Fujita K, Kitamura H. Cell proliferation activity and the expression of cell cycle regulatory proteins in oral lichen planus. J Oral Pathol Med. 2002 Apr;31(4):204-12. doi: 10.1034/j.1600-0714.2002.310403.x. PubMed 12076323 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02834520
Lead sponsor
Cairo University
Responsible party
Noha Ayman Ghallab (Associate Professor of Oral Medicine and Periodontology, Cairo University) — Principal investigator
First posted
Jul 15, 2016
Start date
May 2015
Primary completion
Dec 2015
Completion
Mar 2016
Last update
Jul 15, 2016

Study contacts

Noha Ghallab, MD
principal investigator · Associate Professor of periodontology and Oral Medicine faulty of oral an

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion